AMO-01
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 08/26/2019
Pipeline Type
New Drugs in Development
Phase Of Development
Phase 2
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Mechanism of Action
Mechanism Description
inhibitor of the Ras-ERK pathway.
Populations Tested In
Phelan-McDermid Syndrome (PMS)
Other Resources
Special FDA Designation
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
N/A
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A
Location of Clinical Trials
New York City, Icahn School of Medicine at Mount Sinai
Clinical Trial link